ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Cancers Linked To Agent Orange In IOM Review

August 13, 1993

In Brief: Salmon To Step Down As Center Director; Becker To Relinquish Positions At MDACC

September 4, 1998

Colorado Center Delays New Core Grant Application

July 13, 1979

Cooperative Groups Meet With NCI to Discuss Plan to use Rosenberg’s Regimen At Member Institutions

December 13, 1985

Lurie Center At Northwestern Wins Core Grant Renewal.

December 7, 2001

MEPACT Approved In Europe For Resectable Osteosarcoma

March 27, 2009